We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from Boston Scientific (BSX - Free Report) is expected to reveal quarterly earnings of $0.72 per share, indicating an increase of 16.1% compared to the year-ago period. Analysts forecast revenues of $4.89 billion, representing an increase of 18.7% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Boston Scientific metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Net Sales- MedSurg- Worldwide' to come in at $1.68 billion. The estimate indicates a change of +13.1% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Cardiovascular- Worldwide' of $3.21 billion. The estimate points to a change of +21.7% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- Cardiovascular- Cardiology- Worldwide' will reach $2.52 billion. The estimate points to a change of +23.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Peripheral Interventions- Worldwide' should come in at $689.56 million. The estimate indicates a year-over-year change of +16.9%.
The combined assessment of analysts suggests that 'Geographic Revenue- U.S.' will likely reach $3.06 billion. The estimate indicates a year-over-year change of +24.1%.
Analysts' assessment points toward 'Net Sales- Cardiovascular- Peripheral Interventions- International' reaching $309.92 million. The estimate indicates a year-over-year change of +10.3%.
Analysts predict that the 'Net Sales- MedSurg- Neuromodulation- United States' will reach $220.82 million. The estimate points to a change of +3.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- MedSurg- Neuromodulation- International' should arrive at $70.31 million. The estimate indicates a year-over-year change of +3.4%.
The average prediction of analysts places 'Net Sales- MedSurg- Endoscopy- United States' at $445.09 million. The estimate suggests a change of +7.3% year over year.
Analysts forecast 'Net Sales- MedSurg- Endoscopy- International' to reach $273.79 million. The estimate suggests a change of +4.9% year over year.
It is projected by analysts that the 'Net Sales- MedSurg- Urology- United States' will reach $492.40 million. The estimate indicates a year-over-year change of +35.7%.
The consensus estimate for 'Net Sales- MedSurg- Urology- International' stands at $177.83 million. The estimate suggests a change of +9.8% year over year.
Over the past month, shares of Boston Scientific have returned +3.2% versus the Zacks S&P 500 composite's +5.4% change. Currently, BSX carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS
The upcoming report from Boston Scientific (BSX - Free Report) is expected to reveal quarterly earnings of $0.72 per share, indicating an increase of 16.1% compared to the year-ago period. Analysts forecast revenues of $4.89 billion, representing an increase of 18.7% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Boston Scientific metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Net Sales- MedSurg- Worldwide' to come in at $1.68 billion. The estimate indicates a change of +13.1% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Cardiovascular- Worldwide' of $3.21 billion. The estimate points to a change of +21.7% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- Cardiovascular- Cardiology- Worldwide' will reach $2.52 billion. The estimate points to a change of +23.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Peripheral Interventions- Worldwide' should come in at $689.56 million. The estimate indicates a year-over-year change of +16.9%.
The combined assessment of analysts suggests that 'Geographic Revenue- U.S.' will likely reach $3.06 billion. The estimate indicates a year-over-year change of +24.1%.
Analysts' assessment points toward 'Net Sales- Cardiovascular- Peripheral Interventions- International' reaching $309.92 million. The estimate indicates a year-over-year change of +10.3%.
Analysts predict that the 'Net Sales- MedSurg- Neuromodulation- United States' will reach $220.82 million. The estimate points to a change of +3.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- MedSurg- Neuromodulation- International' should arrive at $70.31 million. The estimate indicates a year-over-year change of +3.4%.
The average prediction of analysts places 'Net Sales- MedSurg- Endoscopy- United States' at $445.09 million. The estimate suggests a change of +7.3% year over year.
Analysts forecast 'Net Sales- MedSurg- Endoscopy- International' to reach $273.79 million. The estimate suggests a change of +4.9% year over year.
It is projected by analysts that the 'Net Sales- MedSurg- Urology- United States' will reach $492.40 million. The estimate indicates a year-over-year change of +35.7%.
The consensus estimate for 'Net Sales- MedSurg- Urology- International' stands at $177.83 million. The estimate suggests a change of +9.8% year over year.
View all Key Company Metrics for Boston Scientific here>>>Over the past month, shares of Boston Scientific have returned +3.2% versus the Zacks S&P 500 composite's +5.4% change. Currently, BSX carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .